Engineered probiotic Bifidobacterium for tumor-targeted pancreatic cancer therapy
Science Advances · 24.07.2026 · 12 (30)
DOI: 10.1126/sciadv.adz1388 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 24.07.2026. Verfasst von Jaehyun Lee und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, University of Chicago, Chicago, IL 60637, USA. Hauptthemen laut MEDLINE: Probiotics, Pancreatic Neoplasms, Interleukin-2, Bifidobacterium. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIAID NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) presents a substantial challenge due to its resistance to cancer treatments. This limited efficacy is, in part, attributed to the immunosuppressive tumor microenvironment (TME), which impairs effector T (T eff ) cell activity. Interleukin-2 (IL-2) is a key cytokine for T cell activation, but its therapeutic use is limited by a short half-life, systemic toxicity, and regulatory T (T reg ) activation. To address this limitation, we engineered Bifidobacterium longum , a probiotic obligate anaerobe that selectively colonizes the TME, to continuously secrete Super-mutant IL-2 (SumIL-2), an engineered IL-2 variant that preferentially activates T eff cells over T reg cells, thereby delivering SumIL-2 selectively to the tumor (BifidoSumIL-2). Systemic administration of BifidoSumIL-2 significantly suppressed tumor growth in both subcutaneous tumors and orthotopic PDAC in mice, inducing an improved T eff /T reg ratio. Combining BifidoSumIL-2 with chemotherapy, radiation, and immunotherapy further restrained orthotopic PDAC growth, highlighting its therapeutic potential for difficult-to-treat cancers like PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, University of Chicago, Chicago, IL 60637, USA.
- Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL 60637, USA.
- The Ludwig Center for Metastasis Research, University of Chicago, Chicago, IL 60637, USA.
- Department of Pathology, University of Texas Southwestern, Dallas, TX 75390, USA.
- Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing 100084, P.R. China.
- Pritzker School of Molecular Engineering, University of Chicago, Chicago, IL 60637, USA.
ORCID-Profile: Jaehyun Lee, Kaiting Yang, Christina A Nowicki, Wei Liu, Kangdi Li, Emile Naccasha, Zhichen Sun, Yang-Xin Fu, Hua Liang, Ralph R Weichselbaum, Mark Mimee
Förderung
- NCI NIH HHS
- NIAID NIH HHS
- National Cancer Institute
- National Institute of Allergy and Infectious Disease
- Ludwig Foundation
Zitieren
APA
Lee, J., Yang, K., Nowicki, C. A., Liu, W., Li, K., Naccasha, E., Sun, Z., Fu, Y. X., Liang, H., Weichselbaum, R. R., & Mimee, M. (2026). Engineered probiotic Bifidobacterium for tumor-targeted pancreatic cancer therapy. Science Advances, 12(30). https://doi.org/10.1126/sciadv.adz1388
Vancouver
Lee J, Yang K, Nowicki CA, Liu W, Li K, Naccasha E, et al. Engineered probiotic Bifidobacterium for tumor-targeted pancreatic cancer therapy. Science Advances. 2026;12(30). doi:10.1126/sciadv.adz1388
BibTeX
@article{Lee2026,
author = {Lee, Jaehyun and Yang, Kaiting and Nowicki, Christina A and Liu, Wei and Li, Kangdi and Naccasha, Emile and Sun, Zhichen and Fu, Yang-Xin and Liang, Hua and Weichselbaum, Ralph R and Mimee, Mark},
title = {Engineered probiotic Bifidobacterium for tumor-targeted pancreatic cancer therapy},
journal = {Science Advances},
year = {2026},
volume = {12},
number = {30},
doi = {10.1126/sciadv.adz1388}
}
EUVIMED